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decreasing trend in average CNI dose by year: at the end of the first year, the mean
dose of TAC was 9.35.4 mg/day and 282.1118.3 mg/day for CYC, decreasing to
5.23.6 and 158.757.8 mg/day in the third year, and 4.87.3 and 144.258.4 mg/
day in the fifth year. At the end of the first (n455) and second year (n408) post-
transplant, the most common IS regimens were TAC/prednisone/mycophenolate
mophetil (MMF) (19.1% in both years), TAC/prednisone/azathioprine (15.6% at first
year and 14.7% at second year) and CyC/prednisone/azathioprine (13.2% at first
year and 14.0% at second year). By the end of the fifth year (n141), however, the
most common IS regimen was TAC/prednisone/mycophenolate sodium (MFS;
31.9%), followed by CyC/prednisone/MFS (7.8%) and TAC/prednisone/MMF (7.1%).
CONCLUSIONS:Tacrolimuswas the CNI of choice for themajority of de novo kidney
transplant patients in 2004. The main IS therapy regimens during the first post-
transplant years was tacrolimus/prednisone/mycophenolate mophetil.
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OBJECTIVES: The employer burden of CKD in terms of lost productivity, short and
long term disability use, and high total health care costs has been well-docu-
mented and warrants an employer-sponsored population health management
program to improve the health and lives of theworkforce. Georgia Power Company
(GPC) has implemented a chronic care management program aimed at early iden-
tification, disease awareness, and counseling of employees through on-site
screenings. METHODS: Individuals are offered voluntary participation in the CKD
management programwith their PCPs andnephrologists depending upon their risk
and CKD stage. Health outcomes including, clinical, resource utilization, and self-
reported health status and productivity are compared pre- and post- program
implementation. RESULTS: Preliminary results at the 6-month mark show that: a)
2,589 employees were screened, 638 (25%) met program criteria for participation
and 110 (17.2%) agreed to participate in the study; b) among the current enrollees,
17% have diabetes and 51% have hypertension; c) mean eGFR rates are 61.27, and
HbA1C levels of 7.7, and a mean BMI of 30.5 indicating a population at high risk for
developing CKD; d) participants reported missing on average 10.5 hours/week due
to their CKD; and e) baseline total health care expenditures were $19,776 permem-
ber per year indicating a high cost population as well. CONCLUSIONS: CKD is a
high-cost disease for GPC. Resources invested in creating novel CKD management
programs to identify, raise awareness, and manage CKD are a worthwhile invest-
ment for employers.
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OBJECTIVES:Many patients with OAB attempt self-management and are reluctant
to initiate an OAB discussion with a physician. We sought to identify patient char-
acteristics associatedwith patient initiation of anOAB discussionwith a physician.
METHODS: Of 24,866 respondents of the 2009 National Health & Wellness Survey,
an internet-based questionnaire onhealthcare attitudes, behaviors, and outcomes,
2750 recontacted respondents qualified for and completed a longitudinal survey.
Eligible subjects (18 y) had an OAB Awareness Total score of 14 (men) or 16
(women) or used an OAB prescription medication. Exclusion criteria included cur-
rent pregnancy or catheter use, hematuria, urinary tract infection symptoms, be-
nign prostatic hyperplasia (BPH), use of BPH medication, or prostate cancer. Anal-
ysis of proportions and logistic regression analysis (2-tailed P0.05 significance
level) identified patient characteristics associated with initiation of OAB discus-
sions with a physician. RESULTS: 1325 of 2750 (48%) OAB patients reported initiat-
ing an OAB discussion with a physician. These respondents (mean age 52 y) were
predominantly female (65%) and white (71%). Significant variables associated with
initiation of an OAB discussion were divorced/separated/widowed vs single, more
familiar with OAB, a longer duration of bladder control symptoms, lower SF-12
Physical Component Summary score, better daily activity function, greater pill
burden, and regular physician contact (Table). Patient age, income, employment
status, and health insurance coverage were not significantly associated with a
patient-physician OAB discussion. CONCLUSIONS: Patients are more likely to ini-
tiate an OAB discussion with their physician if they have regular contact with the
physician, a longer duration of symptoms, are familiar with OAB, and have worse
physical quality of life. Socioeconomic variables or drug insurance coverage were
not significantly associated. These findings suggest that the physician relationship
is important for help seeking behavior; and there is a need for early patient educa-
tion on OAB symptoms and treatments.
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OBJECTIVES: Determine the impact of correcting for different definitions of pros-
tate-specific antigen (PSA) recurrence when analyzing relative effectiveness of
seven treatments for localized PC; Emphasize the importance of clinical input and
real-world data in ensuring modeling accuracy. METHODS: We conducted two
lifetime cost-utility analyses comparing men undergoing open, laparoscopic, or
robot-assisted radical prostatectomy, 3-dimensional conformal or intensity-mod-
ulated radiation therapy, brachytherapy, or combined external-beam radiation
and brachytherapy.We constructed aMarkovmodel quantifying lifetime costs and
quality-adjusted life years (QALYs) for men with localized PC in low-, intermedi-
ate-, and high-risk strata. Post-treatment PSA recurrence is defined differently for
surgical versus radiation treatments. In Study 1, we made clinically-based correc-
tions in time between recurrence and metastasis, the basis for time-to-disease-
progression (biochemical failure [BCF]) calculations, to account for the different
definitions. In Study 2, these corrections were not made. RESULTS: In “corrected”
analyses, surgery tended to yieldmore QALYs and lower costs than radiation, with
minimal differences among surgicalmodalities. Compared to a base case assuming
a 4-year increment between the surgery and radiation modalities in the median
time from BCF to metastasis, “uncorrected” analyses yield surgical costs relatively
overstated by 3 to 11%; QALYs understated by 1 to11%; life expectancy understated
by1% to 8.5%;metastasis overstated by 17 to 36%; and PC death overstated by 17%
to 43%. Results are generally greater with larger corrections and outcomes dis-
counted to net present value. CONCLUSIONS: “Without correction” results do not
affect conclusions about relative costs for all patients or QALYs for low-risk pa-
tients. They do affect QALY conclusions for intermediate- and higher-risk patients,
yielding erroneous conclusions on the relative superiority of radiation versus sur-
gical treatments. Without correction, the same incorrect conclusions would be
reached for survival, metastasis, and PC death. Literature and real-world datawere
used to validate the corrections.
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OBJECTIVES: Selection of an appropriatemodeling structure is a key consideration
in economic evaluations. Factors that influence the choice of modeling structure
include data availability and consensus within the clinical community regarding
clinically meaningful definitions of treatment response and defined and measure-
able health states. In the absence of an agreed consensus, selecting a model struc-
ture is challenging. We explored twomodel structures to assess the cost-effective-
ness of onabotulinumtoxinA for the treatment of urinary incontinence (UI) due to
neurogenic detrusor overactivity (NDO).METHODS: Themerits and limitations of a
model based on treatment response versus an absolute model structure were con-
sidered. In the response model, health states were defined by precise trial out-
comes (percent reduction in UI episodes from baseline). In the absolute model,
health states were defined by categories of UI episodes/week. In the absence of
clinically meaningful cutoffs, we plotted health-related quality of life (HRQoL)
scores versus UI episodes to derive meaningful cutoffs for health states based on
HRQoL. RESULTS: In the response model, response was defined as a 50% reduc-
tion in UI episodes. The primary limitation with this approach is the heterogeneity
within ‘non-responder’ patients (e.g. patients with either a 0% or a 49% reduction
are both ‘non-responders’). No clear health state cutoffs were observed with re-
spect to HRQoL and UI episodes for the absolute model. Health states were defined
on percentile distribution within the trial population: dry, 0-25% [1-14 UI episodes/
week],25%-75% [15-32 UI episodes/week], and75% [32 UI episodes/week]. The
primary limitations to this approach are the inability to capture health improve-
ment within health states and the lack of clinical relevance for health states based
on percentiles. CONCLUSIONS: In the absence of clinical consensus, model struc-
ture selection should be a key consideration to capture the true economic value of
a therapy.
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OBJECTIVES: Retrospective analyses are inherently subject to bias. Techniques
such as propensity score matching (PSM) can function as pseudo-randomization.
The PSM, however, is often done solely using administrative claims data.We tested
the hypothesis that claims alone would provide inadequate matching when com-
pared to claims plus relevant biomarkers. METHODS: We used databases from a
large dialysis organization to obtain two cohorts of dialysis patients prescribed
different drug therapies within the same class. The cohorts were first matched on
demographics and comorbidities only. The same cohorts were then rematched,
adding baseline biomarkers (albumin, corrected calcium, Kt/V, normalized protein
catabolic rate (nPCR), parathyroid hormone (PTH), phosphorus) to the PSM. We
used generalized mixed models (GMM) to determine if treatment was associated
with lab outcomes over a 16-week period, run separately on both PSM cohorts.
RESULTS: The first PSM cohorts did not differ on baseline demographic and comor-
bid variables, but significant differences existed in four (nPCR, phosphorus, cal-
cium, PTH) of the six baseline biomarkers excluded from the match (all p 0.01).
When biomarkers were included in the PSM, there were no significant differences
between groups on any baseline measures. GMM analysis showed a significant
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